23 Jul, 2026
According to Straits Research, the global cell & gene therapy clinical trials market size was valued at $13.93 billion in 2025 and is projected to reach $50.27 billion by 2034, registering a CAGR of 15.37% during the forecast period 2026–2034.
The growth of the cell and gene therapy clinical trials market is primarily driven by the increasing prevalence of genetic and rare diseases, coupled with advancements in gene editing technologies such as CRISPR and CAR-T that enable precise and personalized treatment approaches. However, the market faces a significant restraint due to the high cost and complexity of conducting these trials, including challenges in manufacturing, logistics, and regulatory compliance, which limit accessibility for smaller biotech firms. Despite this, a major opportunity lies in the rising government and private sector investments aimed at expanding clinical research infrastructure and accelerating regulatory approvals, particularly in emerging regions, fostering innovation and wider adoption of advanced therapies.
sales@straitsresearch.com